Gestational age determination and prevention of HIV perinatal transmission

International Journal of Gynecology and Obstetrics

Volumn 92, Issue 2, 2006, Pages 176-180

  Traisathit, P ^a,b,c,g   Le Coeur S ^d   Mary, J Y ^c   Kanjanasing, A ^e   Lamlertkittikul, S ^f   Lallemant, M ^a  

^a Institute of research for development Thailand   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^e Chacheongsao Hospital   (Thailand)

^f Hat Yai Hospital   (Thailand)

^g NONE   (Thailand)

Author keywords

Antiretroviral prophylaxis; Gestational age; HIV; Perinatal transmission; Pregnancy; Thailand

Indexed keywords

ZIDOVUDINE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MENSTRUAL CYCLE; PERINATAL INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; ULTRASOUND; UTERUS FUNDUS HEIGHT;

EID: 30744454012     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2005.09.021     Document Type: Article

References (12)

1. WHO/UNAIDS 2004. AIDS epidemic update: December 2004. UNAIDS/04.45E. Available at: http://www.who.int/hiv/pub/epidemiology/en/epiupdate2004_I_en.pdf. Accessed 10 December 2004.
2. E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, and M.J. O'Sullivan Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment NEJM 331 1994 1173 1180
3. World Health Organization Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV Wkly Epidemiol Rec 73 1998 313 320
4. N. Shaffer, R. Chuachoowong, P.A. Mock, C. Bhadrakom, W. Siriwasin, and N.L. Young Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group Lancet 53 1999 773 780
5. M. Lallemant, G. Jourdain, S. LeCoeur, S. Kim, S. Koetsawang, and A.M. Comeau A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) NEJM 343 2000 982 991
6. J.M. Jimenez, J.E. Tyson, and J.S. Reisch Clinical measures of gestational age in normal pregnancies Obstet Gynecol 61 1983 438 443
7. The European Collaborative Study Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight? AIDS 13 1999 119 124
8. The European Collaborative Study Swiss Mother and Child HIV Cohort Study Combination antiretroviral therapy and duration of pregnancy AIDS 14 2000 2913 2920
9. P. Armitage G. Berry Statistical methods in medical research 1994 Blackwell Scientific Publications Oxford, London 171 172
10. B. Blondel, I. Morin, R.W. Platt, M.S. Kramer, R. Usher, and G. Breart Algorithms for combining menstrual and ultrasound estimates of gestational age: consequences for rates of preterm and postterm birth BJOG 109 2002 718 720
11. S. Prasitwattanaseree, D. Costagliola, M. Lallemant, and J.Y. Mary Modeling of the timing of mother-to-child HIV-1 transmission as a function of zidovudine treatment duration in mothers and infants 12th Conf on Retroviruses and Opportunistic Infections, Feb 22-25, 2005, Boston, USA 2005 Abstract number 780
12. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Available at: http://www.who.int/3by5/arv_pmtct/en/. Accessed 10 December 2004.